

OverView BWGE 2022

PAVILION 1		PAVILION 2	
Room ANTWERP	Room BRUSSELS	Room GENT	Room LIEGE
<p>■ 17.15-19.20 UltraSound Course</p>	<p>■ 08.30-10.10 PGC</p> <p>■ 10.30-12.10 PGC</p> <p>■ 13.15-14.55 PGC</p> <p>■ 15.15-16.55 PGC</p> <p>■ 17.15-18.40 BHMSG</p>		<p>■ 09.00-10.15 IBD - BIRD</p> <p>■ 10.15-10.45 Symposium VIATRIS</p> <p>■ 11.00-12.00 IBD - BIRD</p> <p>■ 12.00-12.45 Symposium GALAPAGOS</p> <p>■ 13.30-14.55 IBD - BIRD</p> <p>■ 14.55-15.25 Symposium ABBVIE</p> <p>■ 15.40-17.05 IBD - BIRD</p> <p>■ 17.30 IBD - BIRD GA</p>
<p>■ 08.30-10.10 BASL - BLIC</p> <p>■ 10.10-10.40 Brohée Lecture</p> <p>■ 10.40-13.10 BASL - BLIC</p> <p>■ 14.00-16.00 BASL - BLIC</p> <p>■ 16.00 BASL - BLIC GA</p>	<p>■ 09.00-10.15 Case Reports</p> <p>■ 10.30-12.00 Case Reports</p> <p>■ 13.00-14.00 BeSPGHAN GA</p> <p>■ 14.00-15.50 BeSPGHAN</p> <p>■ 15.50-16.10 BeSPGHAN</p>	<p>■ 08.30-11.00 GIREM</p> <p>■ 11.15-12.50 GIREM</p> <p>■ 13.30-15.45 GIREM</p>	<p>■ 14.00-15.20 BSGIE</p> <p>■ 15.20-17.15 BSGIE</p>
<p>■ 09.00-12.00 Working Group Digestive Pathology</p> <p>■ 13.00-14.30 Working Group Digestive Pathology</p> <p>■ 14.45-16.00 Working Group Digestive Pathology</p>	<p>■ Symposium MSD/EISAI</p> <p>■ 08.30-10.05 BGDO</p> <p>■ 10.05-10.35 Symposium BMS</p> <p>■ 10.35-12.45 BGDO</p> <p>■ 13.00-14.00 Young BASL</p> <p>■ 14.10-15.10 Young BASL</p> <p>■ 15.15-16.30 Young BASL</p>	<p>■ 09.00-10.30 BSGIE LIVE</p> <p>■ 11.00-12.45 BSGIE LIVE</p> <p>■ 14.00-16.00 Proctology</p>	<p>■ 14.00-16.00 BPC</p>

WEDNESDAY 09/02

THURSDAY 10/02

FRIDAY 11/02

17:15-20:10 - SESSION

**Moderators : L. Vonghia (UZ Antwerpen),
J. Schouten (AZ Nikolaas/UZ Gent)**

- **17:15** **Welcome**
Luisa Vonghia (UZ Antwerpen), Jeffrey Schouten (AZ Nikolaas/UZ Gent)
- **17:20** **Ultrasound of biliary tract and pancreas.**
Luisa Vonghia (UZ Antwerpen)
- **18:15** **Clinical cases (biliary tract and pancreas):**
 - Ultrasound**
Wim Verlinden (AZ Nikolaas/UZ Antwerpen)
 - Echoendoscopy**
Helena Degroote (UZ Gent)
- **18:55** **Intestinal ultrasound in the diagnosis of bowel diseases.**
Jeffrey Schouten (AZ Nikolaas/UZ Gent)
- **19:30** **Intestinal ultrasound in IBD.**
Pieter Dewint (AZ Maria Middelaes/UZ Antwerpen)
- **20:05** **Farewell**
Jeffrey Schouten (AZ Nikolaas/UZ Gent), Luisa Vonghia (UZ Antwerpen)



08:30-10:10 - SESSION 1

Moderators : Philip Roelandt (KUL), Catherine Van Kemseke (ULg)

- 08:30 **Squamous cell carcinoma of the esophagus.
Screening and endoscopic treatment modalities.**
Arnaud Lemmers (ULB)
- 08:55 **Swallowing disorders that are relevant for the gastroenterologist.**
An Moonen (KUL)
- 09:20 **Management of gastric portal hypertension and GAVE.**
Liesbeth Macken (UZA)
- 09:45 **Dumping syndrome.
Diagnosis and treatment options.**
Joris Arts (Brugge/KUL)

■ 10:10 **BREAK**

10:30-12:10 - SESSION 2

Moderators : Philip Roelandt (KUL), Catherine Van Kemseke (ULg)

- 10:30 **Obscure GI bleeding and small intestinal angiodysplasia.
Diagnosis and treatment.**
Tom Moreels (UCL)
- 10:55 **Ischaemic colitis.
Prevention, diagnosis and treatment.**
Sebastien Kindt (VUB)
- 11:20 **Colonic (peri-)diverticulitis.
Antibiotics or not? To cut or not to cut?**
Martin Hiele (KUL)
- 11:45 **Optimizing your colonic adenoma detection rate.**
David Tate (UG)

■ 12:10 **BREAK**



13:15-15:00 - SESSION 3

Moderators : Hubert Piessevaux (UCL), Isabelle Colle (ASZ/UGent)

- 13:15 **Belgian consensus on irritable bowel syndrome.**
Sebastien Kindt (VUB)
- 13:45 **What a gastroenterologist should know about vascular liver disorders.**
Jeffrey Schouten (Sint Niklaas/UG)
- 14:10 **IgG 4 cholangiopathy.**
Hendrik Reynaert (VUB)
- 14:35 **Intraductal Papillary Mucinous Neoplasm of the pancreas.**
Pierre Deprez (UCL)

■ 15:00 **BREAK**

15:20-17:00 - SESSION 4

Moderators : Hubert Piessevaux (UCL), Isabelle Colle (ASZ/UGent)

- 15:20 **Management of peripancreatic collections.**
Pieter Hindryckx (UG)
- 15:45 **Cancer risk and cancer surveillance in IBD.**
Catherine Reenaers (ULg)
- 16:10 **Prognostic markers in colorectal cancer.**
Hans Prenen (UZA)
- 16:35 **Early diagnosis and treatment of cholangiocarcinoma.**
Anne Demols (ULB)



17:30-18:40 - SESSION

Moderators : Hubert LOUIS(ULB Erasme, Brussels),
Annemieke SMET(LEMP, Antwerp)

- 17:30 H01 **Gastric Non-Helicobacter pylori Helicobacter Species (NHPH) and Disease: From animals to clinical relevance in humans.**
E. Taillieu / UGent
- 17:45 **State of the art: Helicobacter pylori resistance to antibiotics in Belgium.**
R. Garces, Y. Miendje / CHU Saint-Pierre Brussels
- 18:00 **Invited Lecture: Recommended and validated treatment regimens in Belgium and Europe.**
Ruffin Ntounda / CHU Saint-Pierre, Brussels
- 18:25 H02 **Differences in Management of Helicobacter pylori Infection: An Observational Study.**
G. Rasschaert, R. Ntounda/ CHU Saint-pierre, Brussels
- 18:40 **End of the session**

09:00-10:15 - SESSION 1

Moderators : M. Ferrante (UZ Leuven), M. Truyens (UZ Gent)

- **09:00** **Invited lecture: Sphingosine 1-phosphate modulation and mechanisms to target immune cell trafficking in IBD.**
 Dr Bram Verstockt / UZ Leuven
- **09:25** I01 **Endoscopic outcome in tofacitinib treated patients correlated with tofacitinib tissue exposure.**
 B. Verstockt (1), D. Alsoud (2), J. Van Oostrom (3), J. Smith (4), J. Stylli (4), S. Singh (4), S. Van Gennep (3), P. Rahimian (4), J. Sabino (1), M. Ferrante (1), S. Singh (4), G. D'haens (3), S. Vermeire (1) / [1] UZLeuven, [2] KULeuven, [3] Amsterdam UMC, The Netherlands, [4] Progenity, San Diego, USA
- **09:35** I02 **Remission state in inflammatory bowel disease patients on anti TNF or vedolizumab: aconfocal endomicroscopy study.**
 J. Loly, S. Vieujean, C. Reenaers, C. Van Kemseke, L. Seidel, J. Somja, E. Louis / CHU Liege
- **09:45** I03 **Biological therapies and small molecules are efficacious in patients with moderate-to-severe ulcerative proctitis.**
 P. Lemmens, J. Sabino, E. Dubois, B. Verstockt, S. Vermeire, M. Ferrante / UZ Leuven
- **09:55** I04 **The dynamic of the molecular classification of Crohn's disease.**
 N. Seyed Tabib (1), S. Verstockt (1), B. Verstockt (2), Sabino (2), M. Ferrante (2), S. Vermeire (2) / [1] KULeuven, [2] UZ Leuven
- **10:05** I05 **Matrix Gla protein, a potential marker of tissue remodelling and physiological ageing of the gut in Crohn's Disease.**
 S. Vieujean (1), P. Delanaye (1), L. Seidel (1), E. Cavalier (1), N. Pierre (2), E. Louis (1) / [1] CHU Liège, [2] U Liège

■ **10:15** BREAK

- **10:15 - 10:45** **Satellite Symposium VIATRIS:**
Post-operative management after ileocecal resection in CD patients.
 Speaker: Triana Lobaton / UZ Gent



11:00-12:45 - SESSION 2

Moderators : J. Geldof (UZ Gent), C. Liefferinckx (ULB)

- 11:00 106 **A randomized placebo controlled clinical trial with 5-hydroxytryptophan in patients with quiescent inflammatory bowel disease and fatigue (Trp-IBD).**
 M. Truyens (1), T. Lobaton Ortega (1), A. Peeters (1), M. Ferrante (2), S. Vermeire (2), P. Bossuyt (3), L. Pouillon (3), P. Dewint (4), A. Cremer (5), H. Peeters (6), G. Lambrecht (7), E. Louis (8), J. Rahier (9), O. Dewit (10), V. Muls (11), T. Holvoet (12), L. Vandermeulen (13), G. Gonzales (14), D. Laukens (1), M. De Vos (1) / [1] UZ Gent, [2] UZ Leuven, [3] Imelda Hospital, Bonheiden, [4] Maria Middelaers Ziekenhuis, Gent, [5] ULB Erasme, Brussels, [6] AZ Sint-Lucas, Gent, [7] AZ Damiaan, Oostende, [8] CHU Liège, [9] CHU UCL Namur, Yvoir, [10] UCL Saint Luc, Brussels, [11] ULB Saint-Pierre, Brussels, [12] AZ Nikolaas, [13] UZ Brussel, [14] Wageningen University and Research, The Netherlands
- 11:10 107 **Distinct molecular profiles between idiopathic cryptoglandular and Crohn-related perianal fistulas.**
 B. Verstockt, S. Verstockt, G. Bislenghi, J. Sabino, M. Ferrante, A. D'hoore, S. Vermeire / UZ Leuven
- 11:20 108 **Efficacy and safety of bone marrow-derived mesenchymal stem cells in refractory perianalfistulae in Crohn's disease: results from a prospective monocentric study.**
 C. Reenaers, S. Vieujean, C. Coimbra, R. Gillard, P. Meunier, L. Boutaffala, E. Louis / CHU Sart Tilman, Liège
- 11:30 **Invited lecture: Lipids in inflammatory bowel disease, an opportunity to control the inflammation?**
 Giulio Muccioli / Louvain Drug Research Institute,

- 12:00 - 12:45 **Satellite Symposium GALAPAGOS: Evolutions in IBD: towards holistically approaching remission.**
 Speakers: Charlie Lees / Edinburgh, UK,
 Bram Verstockt, UZ Leuven



■ 12:45 BREAK

13:30-14:55 - SESSION 3

Moderators : O. DEWIT (UCL), T .LOBATON (UZ Gent)

- 13:30 **Invited lecture: How to treat a severe colitis in 2022? New drugs, new algorithm?**
David Laharie / CHU Bordeaux
- 13:55 I09 **Changes in colectomy for ulcerative colitis during the last two decades: an in-depth retrospective analysis.**
G. Le Cosquer (1), L. Capirchio (2), P. Rivière (1), N. De Suray (2), F. Poullenot (1), B. De Vroey (2), A. Berger (1), M. Denis (2), F. Zerbib (1), R. Bachmann (2), C. Remue (2), B. Celerier (1), D. Leonard (2), Q. Denost (1), A. Kartheuser (2), D. Laharie (1), O. Dewit (2) / [1] CHU Bordeaux, Hôpital Haut Levêque, Pessac, France, [2] UCL Saint-Luc, Brussels
- 14:05 I10 **Efficacy and safety of ustekinumab for chronic antibiotic refractory pouchitis: A Belgian openlabel multicentre pilot study.**
A. Outtier (1), E. Louis (2), O. Dewit (3), G. Schops (1), B. Verstockt (1), J. Sabino (1), S. Vermeire (1), M. Ferrante (1) / [1] UZ Leuven [2] CHU Sart-Tilman, Liège, [3] UCL Saint-Luc, Brussels
- 14:15 I11 **Real-world effectiveness and safety of risankizumab in patients with moderate-to-severe multi-refractory Crohn's disease: a Belgian multi-centric cohort study.**
D. Alsoud (1), D. Franchimont (2), F. D'heygere (3), P. Bossuyt (4), A. Vijverman (5), P. Van Hootegem (6), J. Sabino (7), A. Cremer (2), S. Vermeire (7), M. Ferrante (7) / [1] KULeuven, [2] ULB Erasme, Brussels, [3] AZ Groeninge, Kortrijk, [4] Imelda Hospital, Bonheiden, [5] CHR Citadelle, Liège, [6] AZ Sint-Lucas Brugge, Assebroek/ Brugge, [7] UZ Leuven
- 14:25 I12 **Real-world endoscopic and histologic outcomes are linked to ustekinumab exposure in Ulcerative Colitis.**
D. Alsoud (1), G. Compernelle (1), S. Tops (1), J. Sabino (2), M. Ferrante (2), D. Thomas (1), G. De Hertogh (2), S. Vermeire (2), B. Verstockt (2) / [1] KULeuven, [2] UZ Leuven
- 14:35 I13 **Positioning of ustekinumab affects its effectiveness, drug persistence and serum exposure in Crohn's disease.**
D. Alsoud (1), J. Sabino (2), M. Ferrante (2), S. Vermeire (2), B. Verstockt (2) / [1] KULeuven, [2] UZ Leuven
- 14:45 I14 **Prevalence and outcomes of Sars-cov2 infection in patients with Immune-Mediated Inflammatory Diseases (IMID): a monocentric Belgian population-based retrospective study.**
C. Vuckovic (1), A. Hoyois (2), J. Mungwete (2), L. De Bellefon (2), C. Musala (2), J. Massart (2), S. Di Romana (2), V. Muls (2) / [1] ULB Erasme, Bruxelles, [2] ULB Saint-Pierre

- 14:55 **Satellite Symposium AbbVie:**
The evolution of targets and outcomes in UC (in the last 10 years) and the potential impact of JAK/STAT pathway inhibition.
Speaker: Sebastian Zeissig / Dresden, Germany



- 14:55 **BREAK**

15:40-17:05 - SESSION 4

Moderators : C. REENAERS (ULG), J. SABINO (UZ Leuven)

- 15:40 I15 **Evaluating segmental healing with the modified Mayo endoscopic score (MMES) has a clear additional value in predicting long-term outcome in patients with ulcerative colitis: results from a prospective cohort study.**
M. Lenfant (1), B. Verstockt (2), J. Sabino (2), S. Vermeire (2), M. Ferrante (2) / [1] KU Leuven, [2] UZ Leuven
- 15:50 I16 **Prophylactic versus endoscopy-driven treatment of Crohn's postoperative recurrence: A retrospective, multicentric European study.**
J. Geldof (1), M. Truyens (1), M. Hanssens (1), T. Holvoet (2), A. Elorza (3), V. Bouillon (4), V. Martins (5), K. Argyriou (6), M. Diculescu (7), A. Moens (8), E. Theodoraki (9), J. Pedro (10), P. Nikolaou (11), F. Baert (12), R. Ferreira-Iglesias (13), H. Peeters (14), M. Casanova (15), P. Eder (16), R. Porter (17), T. Karakan (18), F. Mesonero (19), J. Revés (20), E. Van Dyck (21), A. Jauregui-Amezaga (22), M. Mañosa (23), P. Rivière (24), L. Mosquera (25), F. Portela (26), T. Lobaton (1) / [1] UZ Gent, [2] AZ Nikolaas, Sint-Niklaas, [3] Hospital Universitario de Galdalko, Spain, [4] ULB Erasme, Brussels, [5] Algarve University Hospital Center, Faro, Portugal, [6] University Hospital of Larisa, Greece, [7] Carol Davila University of Medicine Bucharest, Romania, [8] Imelda Hospital, Bonheiden, [9] University Hospital Heraklion, Greece, [10] Hospital Santa Maria, Lisbon, Portugal, [11] Venizeleio General Hospital, Heraklion, Greece, [12] AZ Delta, Roeselare, [13] Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain, [14] AZ Sint-Lucas, Ghent, [15] Hospital Universitario de La Princesa, Madrid, Spain, [16] Poznan University of Medical Sciences, Poznan, Poland, [17] Western General Hospital, NHS Lothian, Edinburgh, [18] Gazi University, Ankara, Turkey, [19] Hospital Universitario Ramon y Cajal, Madrid, Spain, [20] Hospital Beatriz Angelo, Lisbon, Portugal, [21] AZ Klina, Brasschaat, [22] UZ Antwerpen, [23] Hospital Universitario Germans Trias i Pujol, Barcelona, Spain, [24] CHU Bordeaux, Hôpital Haut Levêque, Pessac, France, [25] Hospital del Mar, Barcelona, Spain, [26] Hospital and University of Coimbra, Portugal
- 16:00 I17 **Vaccination coverage significantly increased after implementation of a vaccination tool in the electronic patient health record.**
L. Fierens (1), E. De Dycker (2), J. Joly (2), T. Vanhoutvin (2), P. Verschueren (2), P. De Haes (2), P. De Munter (2), J. Sabino (2), S. Vermeire (2), M. Ferrante (2) / [1] KU Leuven, [2] UZ Leuven
- 16:10 I18 **Type of patient education impacts the willingness to switch from an IV to SC of a biological inpatients with IBD: a multicentre, comparative study.**
K. Asnong (1), E. De Dycker (2), E. Hoeffkens (1), P. Geens (2), N. Lembrechts (1), T. Lambrechts (2), I. Van De Schoot (1), A. Paps (2), L. Pouillon (1), S. Vermeire (2), P. Bossuyt (1), M. Ferrante (2) / [1] Imelda Hospital, Bonheiden, [2] UZ Leuven
- 16:20 I19 **Microbiota, not host origin drives ex vivo epithelial response in ulcerative colitis patients and non-IBD controls.**
K. Arnauts, P. Sudhakar, S. Verstockt, C. Lapierre, S. Potche, C. Caenepeel, B. Verstockt, J. Raes, S. Vermeire, J. Sabino, C. Verfaillie, M. Ferrante / KU Leuven
- 16:30 I20 **Standardized fecal microbiota transplantation including microbial based donor selection in active Ulcerative Colitis patients: A randomized, placebo controlled clinical trial.**
C. Caenepeel (1), S. Deleu (1), K. Arnauts (1), J. Vazquez Castellanos (2), S. Braekeleire (1), K. Machiels (1), F. Baert (3), F. Mana (4), L. Pouillon (5), P. Hindryckx (6), T. Lobaton (6), E. Louis (7), D. Franchimont (8), M. Ferrante (1), J. Sabino (1), S. Vieira-Silva (2), G. Falony (2), J. Raes (2), S. Vermeire (9) / [1] KU Leuven, [2] Rega institute, Leuven, [3] AZ Delta, Roeselare, [4] UZ Brussel, Jette, [5] Imelda Hospital, Bonheiden, [6] UZ Gent, [7] CHU of Liège, [8] ULB Erasme, Brussels, [9] UZ Leuven
- 16:40 **Invited lecture: Fecal transplantation in IBD, is there any hope in a near future?**
Harry Sokol / Saint-Antoine Paris, France

■ 17:05 **BREAK**■ 17:30 **BIRD General Assembly**

E-POSTER

- 121 **High acetate concentration reduces inflammation in organoid-derived epithelial monolayer from patients with Ulcerative Colitis.**
S. Deleu (1), K. Arnauts (1), K. Machiels (1), G. Huys (1), J. Thevelein (2), J. Raes (1), S. Vermeire (1) / [1] KULeuven, [2] Erasmus High School, Brussels
- 122 **Predictive models for assessing the response to ustekinumab in Crohn's disease patients.**
A. Hubert (1), J. Toubeau (1), J. Bottieau (1), D. Franchimont (2), F. Vallée (1), C. Liefferinckx (2) / [1] University of Mons, [2] ULB Erasme, Brussels
- 123 **Experience of using the autoimmune nutrition protocol in patients with autoimmune diseases of the digestive tract.**
T. Haurlyenka / Republican Research Center for Radiation Medicine and Human Ecology, Gomel, Belarus
- 124 **Infliximab re-challenge: could it be an option in refractory IBD patients?**
M. Truyens (1), E. Pijoan Comas (2), E. Glorius (1), J. Geldof (1), T. Lobaton Ortega (1) / [1] UZ Gent, [2] Palamós Hospital, Spain
- 125 **Safety analysis of filgotinib for ulcerative colitis: results from the phase 2b/3 SELECTION study and phase 3 SELECTIONLTE long-term extension Study.**
S. Vermeire (1), M. Ferrante (1), S. Schreiber (2), M. Watanabe (3), C. Yun (4), Y. Zhou (4), S. Zhao (4), J. Hsieh (4), U. Moerch (4), G. Rogler (5), E. Loftus Jr (8) / [1] UZ Leuven, [2] University Hospital Schleswig-Holstein, Germany, [3] Tokyo Medical and Dental University, Japan, [4] Gilead Sciences, Inc., California, USA, [5] University Hospital of Zurich, Switzerland, [8] Mayo Clinic College of Medicine, Minnesota, USA
- 126 **Corticosteroid-free remission of Ulcerative Colitis with filgotinib maintenance therapy: post hoc analysis of the phase 2b/3 SELECTION study.**
S. Vermeire (1), M. Ferrante (1), E. Loftus Jr (2), B. Feagan (3), C. Yun (4), J. Hsieh (4), X. Liu (4), S. Zhao (4), U. Moerch (4), W. Sandborn (7), T. Hibi (8) / [1] UZ Leuven, [2] Mayo Clinic College of Medicine, Minnesota, USA, [3] Western University, ON, Canada, [4] Gilead Sciences, Inc., California, USA, [5] University of California San Diego, La Jolla, USA, [8] Kitasato Institute Hospital, Japan
- 127 **Rapidity of symptom improvements during filgotinib induction therapy in patients with Ulcerative Colitis: post hoc analysis of the phase 2b/3 SELECTION study.**
M. Ferrante (1), S. Vermeire (1), S. Danese (2), T. Hibi (3), T. Ritter (4), J. Dinoso (5), J. Hsieh (5), C. Yun (5), J. Zhang (5), S. Zhao (5), E. Loftus Jr (8), G. Rogler (9) / [1] UZ Leuven, [2] Humanitas Clinical and Research Center, Italy, [3] Kitasato Institute Hospital, Japan, [4] GI Alliance, Texas, USA, [5] Gilead Sciences, Inc., California, USA, [8] Mayo Clinic College of Medicine, Minnesota, USA, [9] University Hospital of Zurich, Switzerland
- 128 **Early achievement of partial Mayo score remission and IBDQ normalization in patients with ulcerative colitis treated with filgotinib in the phase 2b/3 SELECTION study.**
M. Ferrante (1), S. Vermeire (1), A. Oortwijn (2), B. Feagan (3), C. Yun (4), J. Zhang (4), L. Peyrin-Biroulet (5), S. Danese (6) / [1] UZ Leuven, [2] Galapagos BV, The Netherlands, [3] Western University, ON, Canada, [4] Gilead Sciences, Inc., California, USA, [5] Nancy University Hospital, France, [6] Humanitas Research Hospital, Italy
- 129 **The clinical decision support tool has low performance in predicting outcome to ustekinumab in Crohn's disease.**
D. Alsoud (1), J. Sabino (2), M. Ferrante (2), B. Verstockt (2), S. Vermeire (2) / [1] KULeuven, [2] UZ Leuven
- 130 **Associations of blood derived immune cell transcriptional signatures with disease location in IBD.**
P. Sudhakar (1), B. Verstockt (2), J. Cremer (1), S. Verstockt (1), J. Sabino (2), M. Ferrante (2), S. Vermeire (2) / [1] KULeuven, [2] UZ Leuven
- 131 **Surveying the use of Complementary Alternative Medicines among IBD Patients.**
P. Sudhakar (1), R. Stiers (2), E. De Dycker (2), P. Geens (2), A. Paps (2), T. Lambrechts (2), B. Keersmaekers (2), J. Sabino (2), M. Ferrante (2), S. Vermeire (2), B. Verstockt (2) / [1] KULeuven, [2] UZ Leuven
- 132 **Subcutaneous infliximab CT-P13 in clinical practice: A Belgian single center experience.**
L. Cornelis, E. De Jonckere, J. Bossuyt, H. Vanpoucke, L. Desomer, D. De Wulf, F. Baert / AZ Delta, Roeselare

09:00-10:40 - SESSION 1

Moderators : W. Verlinden (AZ Nikolaas/UZA), X. Verhelst (UZ Gent)

- 09:00 A01 **Toll-like receptor 2 activation in monocytes of alcohol use disorder patients contributes to systemic inflammation and alcohol-associated liver disease.**
J.I. Maccioni (1), J. Kasavuli (1), S. Leclercq (1), B. Pirlot (1), G. Laloux (1), Y. Horsmans (2), I. Leclercq (1), B. Schnabl(3), P. Stärkel (1) / [1] UCL, Brussels, [2] UCL Saint-Luc, Brussels, [3] University of California San Diego, La Jolla, USA
- 09:10 A02 **Accuracy of non-invasive techniques compared to magnetic resonance spectroscopy to evaluate the presence of fatty liver disease in individuals with type 1 diabetes: INITIATE1 study.**
J. Mertens, M. Spinhoven, E. Dirinck, L. Vonghia, C. De Block, S. Francque / UAntwerp/UZAntwerp
- 09:20 A03 **Single-cell atlas of adipose tissue macrophages in non-alcoholic fatty liver disease.**
M. Boesch (1), H. Korf (1), R. Feie-Azevedo (1), A. Lindhorst (2), E. Deleus (3), M. Lannoo (3), L. Smets (1), L. Van Melkebeke (1), M. Wallays (1), T. Roskams (1), P. Bedossa (4), J. Verbeek (1), T. Voet (1), A. Sifrim (1), M. Gericke (2), S.van Der Merwe (1) / [1] KUL, Leuven, [2] Leipzig University, Germany, [3] UZLeuven, [4] Beaujon Hospital Paris Diderot University, France
- 09:30 A04 **Single center experience with intestinal transplantation.**
M. Clarysse, A. Dubois, L. Ceulemans, E. Canovai, I. Jochmans, L. Wauters, M. Hiele, T.vanuysel, D. Monbaliu, J. Pirenne / UZ Leuven - KULeuven
- 09:40 A05 **Deletion of Hepatic Glutamine Synthetase Promotes NASH and NASH-Associated HCC.**
C. Pichon, M. Nacht, I. Leclercq / UCL, Brussels
- 09:50 A06 **Ductular bilirubinostasis is independently associated with the development of ACLF at short term: results of a prospective study.**
L. Van Melkebeke (1), T. Ostyn (1), A. Broekhoven (2), H. Verspaget (2), S. Van Der Merwe (1), J. Verbeek (1), M. Coenraad (1), T. Roskams (1), F. Nevens (1) / [1] KULeuven, [2] Leiden University Medical Center (LUMC), Netherlands (the)
- 10:00 A07 **Monocyte signatures of recovery- and non-recovery ACLF patients – uncovering functional, transcriptomic and metabolic dynamics.**
R. Furtado Feio De Azevedo (1), H. Korf (1), M. Boesch (1), S. Radenkovic (2), Wallays (1), L. Smets (1), L. Van Melkebeke (1), B. Ghesquière (2), D. Cassiman (3), P. Meersseman (3), H. Van Malenstein (3), F. Nevens (3), W. Laleman (3), J. Verbeek (3), S. Van Der Merwe (3) / [1] KULeuven, [2] VIB Center for Cancer Biology, Leuven, [3] UZLeuven
- 10:10 **Brohée lecture: «Finding a cure for liver fibrosis in a dish».**
Leo van Grunsven (VUB)
- 10:40 **BREAK**

11:10-11:40

- 11:10 **BELIAC lecture: Waiting time should be training time.**
Diethard Monbaliu – KULeuven

11:40-13:05 - SESSION 2

Moderators : G. Dahlqvist (UCL), E. Trepo (ULB)

- 11:40 A08 **A history of bariatric surgery is independently associated with a younger age of severe alcoholic hepatitis onset, but is not associated with short-term survival.**
L. Van Melkebeke (1), T. Ostyn (1), A. Broekhoven (2), M. Coenraad (2), H. Korf (1), T. Roskams (1), S. Van Der Merwe (1), F. Nevens (1), J. Verbeek (1) / [1] KULeuven, [2] Leiden University Medical Center (LUMC), Leiden, The Netherlands
- 11:52 A09 **Utility and prognostic value of diagnosing metabolic dysfunction-associated fatty liver disease (MAFLD) in patients undergoing liver transplantation for alcohol-related liver disease.**
B. Vanlerberghe, H. Van Malenstein, M. Sainz-Barriga, D. Monbaliu, S. Van Der Merwe, J. Pirenne, F. Nevens, J. Verbeek / UZLeuven
- 12:04 A10 **Prevalence, prognosis and features of incidentally detected hepatocellular carcinoma in explanted livers.**
E. Kerstens (1), S. Iesari (2), G. Dahlqvist (1), E. Bonaccorsi (1), L. Coubeau (1), O. Ciccarelli (1), B. Delire (1) / [1] UCL Saint-Luc, [2] Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, , Italy
- 12:16 A11 **Validation of a glycomics-based test associated with risk of HCC development in cirrhosis.**
X. Verhelst (1), L. Meuris (2), R. Colman (3), A. Geerts (1), A. Van Hecke (2), N. Callewaert (2), H. Van Vlierberghe (1) / [1] UZ Gent, [2] VIB, Gent, [3] UGent
- 12:28 A12 **Tacrolimus drug exposure level in the first year after liver transplantation is an independent risk factor for de novo malignancy in patients transplanted for alcohol-related liver disease.**
B. Vanlerberghe, H. Van Malenstein, M. Sainz-Barriga, D. Monbaliu, S. Van Der Merwe, J. Pirenne, F. Nevens, J. Verbeek / UZLeuven
- 12:40 A13 **Benefit of regular screening for hepatitis delta and subsequent cirrhosis among chronic hepatitis B carriers.**
T. Serste (1), H. Njimi (2), M. Nkuize (1), M. Van Gossum (1), P. Eisendrath (1), J. Mulkay (3) / [1] CHU Saint-Pierre, Brussels, [2] ULB Erasme, Brussels
- 12:52 A14 **Pretransplant changes in serum protein glycosylation relate to risk of HCC recurrence after liver transplantation and provide a potential prognostic biomarker: a proof-of-concept study.**
X. Verhelst (1), H. Engels (1), A. Geerts (1), A. Vanlander (1), L. Abreu De Carvalho (1), H. Degroote (1), L. Meuris (2), F. Berrevoet (1), N. Callewaert (2), H. Van Vlierberghe (1) / [1] UZ Gent [2] VIB, Gent
- 13:10 **BREAK**

14:00-14:30

Moderator : T. Vanwolleghem (UA)

- 14:00 **Marc Hautekeete Lecture: Cessation of Nucleos(t)ide Analogues in chronic HBV: do's and don'ts" (Title TBC).**
Harry Janssen -UHN Toronto, Canada

14:30-15:40 - SESSION 3

Moderators : J. Delwaide (ULiege), R. Reynaert (VUB)

- 14:30 A15 **Abstinence is associated with better outcome in patients with alcohol-related hepatocellular carcinoma.**
A. Donati (1), J. Henrion (2), M. Regnier (1), P. Deltenre (3), A. Marot (1) / [1] CHU Mont-Godinne, [2] Hôpital Jolimont, [3] Saint-luc Bouge, Namur
- 14:40 A16 **The evolving pattern of hepatocellular carcinoma in a general hospital from central Belgium... The history of our region made the difference!**
E. Kaze, J. Henrion / Hôpital Jolimont
- 14:50 A17 **Point of care screening tests for hepatitis B and commitment of a dedicated nurse lead to successful linkage to care of ethnic minorities.**
A. Vanderlinden, E. Ho, L. Govaerts, B. De Fooz, P. Van Damme, P. Michielsens, T. Vanwolleghem / UAntwerp/UZ Antwerpen
- 15:00 A18 **Excellent outcome and vaccination rate in patients with autoimmune hepatitis during the COVID-19 pandemic.**
H. De Sutter, H. Degroote, H. Van Vlierberghe, X. Verhelst / UZGent
- 15:10 A19 **Is insulin resistance the predisposing factor for fatty liver disease in type 1 diabetes?**
J. Mertens, M. Spinhoven, E. Dirinck, L. Vonghia, C. De Block, S. Francque / UAntwerpen/UZAntwerpen
- 15:20 A20 **Assessment of a transient elastography in predicting the graft fibrosis after liver transplantation and validation of the Venturi score in an adult population.**
C. Dumont (1), N. Lanthier (1), S. Iesari (2), G. Henin (1), E. Bonaccorsi-Riani (1), O. Ciccarelli (1), L. Coubeau (1), P.baldin (1), S. Aydin (1), G. Dahlqvist (1) / [1] UCL Saint-Luc, [2] Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Italy
- 15:30 A21 **Prospective validation of the Polycystic Liver disease complaint-specific assessment (POLCA) score: Influence of Menopause and Somatostatin-analogues.**
A. Billiet (1), F. Temmerman (1), W. Coudyzer (1), N. Van Den Ende (1), I. Colle (2), S. Francque (3), H. Thien Anh (4), S. De Maeght (5), F. Janssens (6), H. Orlent (7), D. Sprengers (8), J. Delwaide (9), S. Decock (10), C. De Vloo (11), S. Van Der Merwe (1), J. Verbeek (1), F. Nevens (1) / [1] UZLeuven, [2] ASZ, Aalst, [3] UZAntwerpen, [4] UCL, Brussels, [5] Grand Hopital de Charleroi, [6] Jessa Hospital, Hasselt, [7] AZ Sint-Jan Brugge-Oostende, Brugge, [8] GZA, Antwerp, [9] CHU Liege, [10] AZ Sint-Lucas Brugge, [11] AZ Delta, Roeselare
- 15:40 **BASL Best Basic and Clinical Presentation Prize**
- 15:40 **BASL General Assembly**

E-POSTERS

Moderator : S. Negrin-Dastis (GH Charleroi)

- A22 **Murine bile duct ligation induces liver function failure, neurometabolic changes and microglial activation indicative of hepatic encephalopathy.**
 W. Claeys (1), L. Van Hoecke (2), A. Geerts (1), X. Verhelst (1), H. Van Vlierberghe (1), S. Lefere (1), H. Degroote (1), G. Van Imschoot (2), E. Van Wonterghem (2), R. Vandenbroucke (2), C. Van Steenkiste (3) / [1] UGent, [2] VIB, Gent, [3] UZAntwerpen
- A23 **Small changes in the metabolism of bile acids by the gut microbiota are associated to NASH pathogenesis.**
 J. Gillard (1), M. Thibaut (1), M. Roumain (1), G. Muccioli (1), A. Tailleux (4), B. Staels (4), L. Bindels (1), I. Leclercq (1) / [1] UCLouvain, [2] CHU Lille, France
- A24 **AP-1 and YAP1-TEAD drive independent transcriptional programs to activate hepatic stellate cells.**
 V. De Smet, E. Van Os, S. Verhulst, I. Mannaerts, L. Van Grunsven / VUB, Jette
- A25 **Real-life multi-center retrospective analysis on nivolumab in difficult-to-treat patients with advanced hepatocellular carcinoma.**
 N. De Wilde (1), A. Bucalau (2), G. Verset (2), L. Vonghia (3), S. Francque (3), C. Van Steenkiste (4) / [1] UZ Gent, [2] ULB Erasme, Bruxelles [3] UZAntwerpen, [4] AZ Maria Middelaes, Gent
- A26 **Chronic liver disease, not especially at the cirrhosis stage, is associated with insulin resistance and confers a risk of type 2 diabetes mellitus.**
 G. Bale (1), F. Clarembeau (1), P. Stärkel (1), G. Dahlqvist (1), Y. Horsmans (1), N. Lanthier (1) / [1] UCL Saint-Luc, Bruxelles
- A27 **Early Kupffer cell depletion does not affect hepatocellular carcinoma progression in mice.**
 B. Vanderborght (1), K. De Muynck (1), C. Scott (2), A. Beschin (3), M. Guilliams (2), H. Van Vlierberghe (1), L. Devisscher (1) / [1] UGent, [2] VIB, Gent, [3] VUB, Jette
- A28 **Two diseases, one model - assessing the suitability of FOZ mice to examine CVD in NAFLD.**
 S. Bott, L. Dumas, C. Dessy, I. Leclercq / UCL
- A29 **Prebiotics' plus Probiotics' effect on the patients with Nonalcoholic Fatty Liver Disease.**
 T. Khachidze / Grigol Robakidze University, Tbilisi, Georgia
- A30 **Awareness of chronic hepatitis B and C among men who have sex with men (MSM): epidemiological survey and on-site screening.**
 M. Coessens (1), T. Holvoet (2), J. Schouten (2), W. Verlinden (2) / [1] UZ Antwerpen, [2] AZ Nikolaas

09:00-10:15 - SESSION 1

Moderators : T. Steinhauser (UZ Antwerpen), C. Vankemseke (CHU Liège)

- 09:00 C01 **Large superficial squamous cell carcinoma in the setting of achalasia treated by Endoscopic Submucosal Dissection (ESD): particular features of superficial carcinoma on stasis related esophageal hyperkeratosis.**
L. Mesureur (1), R. Yared (1), L. Verset (2), J. Van Laethem (1), H. Louis (1), J. Devière (1), A. Lemmers (1) / [1] ULB Erasme, [2] Institut Jules Bordet, Brussels
- 09:15 C02 **Gastric peroral endoscopic myotomy (G-POEM) for refractory postsurgical gastroparesis.**
P. Casteels / VUB, Jette
- 09:30 C03 **An unusual location of abdominal gas.**
P. Corens (1), J. Derdeyn (2), I. Baar (3), L. Vonghia (2), T. Steinhauser, T. Vanwollegheem, S. Francque, W. Kwanten / UZ Antwerpen
- 09:45 C04 **Infectious disease mimicking a metastatic rectal cancer.**
N. El Nakadi, L. Mans, A. Buggenhout, N. Bachir / ULB Erasme, Brussels
- 10:00 C05 **Not So Sweet.**
V. Bouillon, A. Cremer, R. Chapusette, T. Gustot, D. Franchimont / ULB Erasme, Brussels

■ 10:15 BREAK

10:30-11:45 - SESSION 2

Moderators : T. Steinhauser (UZ Antwerpen), C. Vankemseke (CHU Liège)

- 10:30 C06 **The gall bladders' Sisyphean task resulting in gastric outlet Obstruction.**
G. Vermeersch, N. Cruyt, M. Cool, G. Deboever, J. Geers, D. Persyn, G. Lambrecht / AZ Damiaan, Oostende
- 10:45 C07 **Three cases of acute liver injury after COVID19 vaccination.**
L. Hulst / AZ Sint Maarten, Mechelen
- 11:00 C08 **Shigellosis: a not-to-be-overlooked STD in MSM.**
M. Van Herck, F. Gillis, F. Couturier, S. Nullens, P. Steger / GZA Sint-Vincentius ziekenhuis, Antwerpen
- 11:15 C09 **Stauffer syndrome: something to keep in mind.**
J. Vandewinckele (1), L. Harlet (2) / [1] UZ Gent, [2] AZ Delta, Roeselare
- 11:30 C10 **Crohn disease onset in a patient treated with IL-17 inhibitor for refractory psoriasis.**
M. Abdessalami, M. Zeriouh, A. Cremer, C. Liefferinckx / ULB Erasme, Bruxelles

■ 13:00-14:00 General Assembly BeSPGHAN

14:00-15:50 - SESSION 1

Moderators : S. Vandeveldel (UZ Gent-U Gent,),
D. Ysebaert (UZ Antwerpen)

- 14:00 **Invited Lecture: New ESPGHAN guideline on diagnosis of malnutrition.**
Koen Huysentruyt / UZ Brussel
- 14:20 **Invited Lecture: GLIM criteria for the diagnosis of malnutrition in adults.**
Andre Van Gossum / ULB Erasme Bruxelles
- 14:40 **Discussion**
- 14:50 K01 **The threat of accidental supermagnet ingestions.**
Ph. Alliet, E. Janssens / Jessa Hospital, Hasselt
- 15:00 **Invited Lecture: Methodological aspects of body composition measurement in infants and children.**
Mary Fewtrell (University College London, UK)
- 15:20 **Invited Lecture: Body composition in health and disease in adults.**
Jean-Paul Thissen / UCL Saint-Luc, Brussels
- 15:40 **Discussion**
- 15:50 **BREAK**

16:10-17:30 - SESSION 2

Moderators : I. Hoffman (UZ Leuven-KULeuven),
V. Fraipont (CHR Citadelle, Liège)

- 16:10 K02 **An unusual rectal protrusion in a two-year-old girl caused by a rectal duplication cyst: case report and literature review.**
E. Levy (1), Y. Vandenplas (2), K. Huysentruyt (2), B. Hauser (2), C. Vercauteren (2), K. Vanderlinden (2), E. De Greef (2), D. Vervloesem (3), T. Devreker (2) / [1] CHU Saint-Pierre, Brussels, [2] UZ Brussel, Jette, [3] ZNA Antwerpen
- 16:20 K03 **COVID-19 pandemic impact: Delay in presentation and altered disease course in children with gastrointestinal and hepatic disorders in a tertiary care center.**
A. Ravindranath, R. Wadhwa / Apollo BGS Hospital, Mysore, India
- 16:30 **Invited Lecture: Refeeding syndrome: definition and prevention in 2021.**
Alexandra Bobarnac / CHC Liège
- 16:50 **Invited Lecture: Management of intestinal failure.**
Tim Van Uytsel / UZ Leuven
- 17:10 **Invited Lecture: Transition clinic in Nutrition.**
Karsten Vanden Wyngaert / UZ Gent
- 17:30 **Conclusion**
Patrick Bontems / ULB HUDERF

08:30-10:55 - SESSION 1

Moderators : A. Smet (UAntwerpen), L. Van Oudenhove (KU Leuven)

- 08:30 **Invited Lecture: Of bowels, brain and behavior: The Microbiota-Gut-Brain Axis in Psychiatry and Beyond.**
Gerard Clarke (University College Cork, Ireland)
- 09:15 B01 **Distinct mucin-microbiome signatures in patients with gastric cancer.**
B. Oosterlinck (1), T. Breugelmans (1), W. Arras (1), J. De Man (1), K. Gebous (2), J. Kupcinkas (3), A. Link (4), M. Peeters (5), B. De Winter (1), A. Smet (1) / [1] U Antwerpen, [2] UZ Gent, [3] Lithuanian University of Health Sciences, Kaunas, Lithuania, [4] Otto von Guericke University Magdeburg, Germany, [5] UZ Antwerpen
- 09:30 B02 **Short chain fatty acids affect stem cell differentiation towards the entero-endocrine cell lineage in obese enteroids.**
M. Farhadipour (1), M. Clarysse (2), K. Arnauts (1), K. Liszt (1), T. Thijs (1), L. Ceulemans (1), E. Deleus (2), B. Van Der Schueren (2), M. Lannoo (2), M. Ferrante (1), I. Depoortere (1) / [1] KULeuven, [2] UZLeuven
- 09:45 B03 **Eosinophil depletion partially protects from intestinal inflammation, but results in increased collagen deposition in a DSS colitis model.**
I. Jacobs, S. Deleu, J. Cremer, J. Guedelha Sabino, M. Ferrante, S. Vermeire, C. Breyneart, B. Verstockt, T. Vanuytsel / KULeuven
- 10:00 B04 **Early Kupffer cell depletion does not affect sclerosing cholangitis progression in mice.**
K. De Muynck (1), B. Vanderborgh (1), C. Scott (1), M. Guilliams (1), A. Beschin (2), X. Verhelst (1), L. Devisscher (1) / [1] Ugent, [2] VUB, Jette
- 10:15 B05 **Gut-Kidney Crosstalk In Chronic Kidney Disease: Remote Sensing Of Indole-Derived Uremic Toxins.**
M. Lauriola, S. Dejongh, R. Farré, K. Verbeke, B. Meijers / KULeuven
- 10:25 B06 **Pitch: A single-cell survey of colorectal epithelial cells unveils multiple cellular perturbations in patients with gastrointestinal disorders.**
A. Denadai-Souza (1), Y. Wu (1), E. Modave (1), X. Abalo (2), L. Larsson (2), J. Aguilera-Lizarraga (1), S. Giacomello (2), T. Lefevre (1), K. Vandereyken (1), K. Van Beek (1), K. Bellens (1), J. Sabino (1), S. Vermeire (1), M. Ferrante (1), A. Sifrim (1), J. Lundberg (2), T. Voet (1), G. Boeckxstaens (1) / [1] KUL Leuven, [2] Karolinska University Hospital, Sweden
- 10:35 B07 **Pitch: Mucin mRNA isoform signatures as potential novel biomarkers to evaluate disease status in patients with inflammatory bowel diseases (IBD).**
W. Arras, T. Breugelmans, B. Oosterlinck, H. De Schepper, M. Somers, E. Macken, F. Van Aert, J. De Man, A. Jauregui-Amezaga, B. De Winter, A. Smet (1) / U Antwerpen/ UZ Antwerpen
- 10:45 B08 **Pitch: Alterations of the differentiation and proliferation programs in the intestinal epithelium compartment contribute to the gut barrier dysfunction in alcohol use disorder patients.**
J. Lupianez (1), L. Maccioni (1), S. Ravau (1), I. Leclercq (1), P. Stärkel (1) / UCL, Brussels
- 10:55 BREAK

11:15-12:50 - SESSION 2

Moderators : H. de Schepper (U Antwerp) & T. Vanuytsel (KU Leuven)

- 11:15 B09 **Volatile organic compound (VOC) profiling in breath and faecal samples discriminates patients with irritable bowel syndrome from healthy.**
K. Van Malderen (1), N. Hanning (2), H. Lambrechts (2), T. Haverhals (2), S. Van Marcke (2), J. De Man (2), B. De Winter (2), K. Lamote (2), H. De Schepper (1) / [1] UZ Antwerpen, [2] U Antwerpen
- 11:30 B10 **The six-food elimination diet improves symptoms in functional dyspepsia.**
K. Routhiaux, J. Schol, E. Roelants, K. Van Den Houte, J. Tóth, I. Huang, F. Carbone, T. Vanuytsel, J. Tack / KU Leuven
- 11:45 B11 **Censoring reflux episodes by the Wingate consensus reduces supportive evidence for GERD provided by pH/impedance monitoring.**
S. Kindt, M. Surmont / UZ Brussel, Jette
- 12:00 B12 **Pitch: Relevance of the diagnosis of autoimmune gastritis in patients with autoimmune thyroiditis.**
T. Haurlyenka / Republican Research Center for Radiation Medicine and Human Ecology, Gomel, Belarus
- 12:10 B13 **Pitch: The prevalence of gastrointestinal symptoms during acute COVID-19 infection assessed using a digital questionnaire.**
K. Van Malderen, J. De Man, B. De Winter, H. De Schepper / U Antwerpen
- 12:20 B14 **Pitch: Differences in caloric intake and macronutrient composition in FD and IBS cohorts compared to healthy subjects.**
S. Pellens, K. Van Den Houte, F. Carbone, J. Tack / KULeuven
- 12:30 B15 **Pitch: Lack of effect of intravenous corticotropin-release hormone on anxiety scores and duodenal permeability in healthy subjects.**
J. Luca, J. Schol, J. Tóth, K. Van Den Houte, I. Huang, F. Carbone, T. Vanuytsel, J. Tack / KULeuven
- 12:40 B16 **Pitch: Duodenal inter-cryptal but not villous eosinophils are increased in functional dyspepsia and affected by inter-rater disagreement.**
P. Huyghe (1), M. Ceulemans (1), G. De Hertogh (2), J. Tack (1), L. Wauters (1), T. Vanuytsel (1) / [1] KULeuven, [2] UZ Leuven
- 12:50 BREAK

13:30-15:45 - SESSION 3

Moderators : G. Matteoli (KU Leuven), W. Boesmans (UHasselt)

- **13:30** B17 **Neuro-immune Crosstalk in the Myenteric Plexus from Early Postnatal Development to Adulthood.**
 M. Viola, M. Chavero Pieres, M. Elodie, N. Stakenborg, S. Alejandro, K. Vandereyken, J. Van Herck, T. Martens, T. Voet, P. Vanden Berghe, B. Guy / KULeuven
- **13:45** B18 **Mrgprb2-mediated signaling represents a novel mast cell degranulation pathway in the mouse colon.**
 S. Van Remoortel, L. Lambeets, J. De Man, B. De Winter, S. Ibiza Martinez, J. Timmermans / U Antwerpen
- **14:00** B19 **MicroRNA profiling of enteric glia status.**
 A. Holland (1), A. Bon-Frauches (2), F. Progzatzky (3), D. Keszthelyi (2), D. Jonkers (2), V. Pachnis (3), V. Melotte (2), W. Boesmans (1) / [1] Hasselt University, [2] Maastricht University Medical Center, The Netherlands, [3] The Francis Crick Institute
- **14:15** B20 **Gliadin cytotoxicity on enteric glial cells: novel insights on celiac pathogenesis based on a new enteric glial cells in vitro model.**
 L. Zanoletti (1), A. Valdata (2), K. Nehlsen (3), P. Faris (2), C. Casali (2), R. Cacciatore (2), I. Sbarsi (2), F. Milella (2), F. Carriero (2), C. Martinelli (2), G. Barbieri (2), L. Van Baarle (1), V. De Simone (1), E. Raimondi (2), T. May (3), F. Moccia (2), G. Matteoli (1), S. Comincini (2), F. Manai (2) / [1] KULeuven, [2] University of Pavia, Italy, [3] InScreenEx GmbH, Braunschweig, Germany
- **14:30** B21 **Live Imaging of Primary Neurons in Long-Term Cryopreserved Human Nerve Tissue.**
 M. Fortea (1), P. Jain (1), I. Demedts (2), J. Tack (2), T. Vanuytsel (2), C. Cirillo (3), P. Vanden Berghe (1) / [1] TARGID, KU Leuven, [2] UZ Leuven, [3] Toulouse NeuroImaging Center, France
- **14:45** B22 **Pitch: Study of neurodegeneration and gastrointestinal motility During diet-induced obesity.**
 M. Chavero Pieres, M. Viola, G. Boeckxstaens / KULeuven
- **15:00** B15 **Invited Lecture: Enteric nervous system evolution in the blind Mexican cavefish.**
 Misty Riddle (University of Nevada, Reno, USA)
- **15:45** **Closing remarks**

14:00-15:20 - SESSION 1

Moderators : A. Lemmers (ULB Erasme, Brussels),
R. Bisschops (UZLeuven),
S. Van Langendonck (AZ Maria Middelaes, Gent)

- 14:00 **Introduction**
Raf Bisschops, BSGIE President
- 14:05 **Invited Lecture: How to improve tissue sampling in upper GI endoscopy? ESGE recommendations.**
Rose Pouw /Amsterdam, The Netherlands
- 14:25 G01 **Using the ESGE Quality Check App in a non-academic endoscopy unit: how much does it cost and what are the barriers?**
S. Bourseau (1), B. Bastens (1), R. Bisschops (2), P. Leclercq (1) / [1] CHC Liège, [2] UZ Leuven
- 14:31 G02 **Local injection of triamcinolone acetonide with selected add-on oral steroids therapy after extensive esophageal endoscopic submucosal dissection to prevent post-ESD stricture: first report of a prospective validation protocol in Western countries.**
D. Carpentier (1), G. Englebort (1), A. Bucalau (1), L. Verset (2), P. Demetter (2), P. Eisendrath (1), J. Deviere (1), A. Lemmers (1) / [1] CUB Erasme, [2] Institut Jules Bordet, Brussels
- 14:37 G03 **Feasibility of implementing the use of regular arrangement of collecting venules in daily endoscopy practice without previous training: early results from a prospective observational study.**
G. Rasschaert, L. Vandermeulen, M. Schiils / UZ Brussel
- 14:41 G04 **Balloon-assisted enteroscopy and motorized spiral enteroscopy: competitive or complementary techniques?**
T. Moreels, L. Monino, P. Deprez, H. Piessevaux / UCL Saint-Luc
- 14:45 **Discussion**
- 14:55 G05 **The Accuracy of Human Detection of Submucosal Invasive Cancer – Analysis of 739 Individual Assessments of Large Non-Pedunculated Colorectal Polyps (LNPCPs) Using a Novel Clinical Decision Support Tool.**
L. Debels (1), C. Schoonjans (1), A. Hoorens (1), L. Desomer (2), J. Anderson (4), R. Valori (5), D. Tate (1) / [1] UZ Gent, [2] AZ Delta, Roeselare, [4] Cheltenham General Hospital, UK, [5] Gloucestershire Royal Hospital, UK
- 15:01 G06 **Low risk of local recurrence after a successful en bloc Endoscopic Submucosal Dissection for colorectal lesions with positive horizontal resection margins (R-ESD study).**
M. Figueiredo Ferreira (1), K. Haasnoot (2), F. Baldaque-Silva (3), A. Koch (4), J. Santos-Antunes (5), E. Dias (5), M. Omae (3), L. Van Tilburg (4), H. Dang (6), J. Boonstra (6), L. Moons (2), A. Lemmers (1) / [1] ULB Erasme, Bruxelles, [2] University Medical Center Utrecht, The Netherlands, [3] Karolinska Institutet, Karolinska University Hospital, , Sweden, [4] Erasmus MC, Rotterdam, The Netherlands, [5] University Hospital S o João , Porto, Portugal, [6] Leiden University Medical Center (LUMC), The Netherlands
- 15:07 G07 **Paired working combined with on-demand direct expert supervision allows a safe and effective implementation of rectal endoscopic submucosal dissection in a non-academic referral hospital.**
G. Bastens (1), O. Plomteux (1), N. Bletard (1), P. Demaret (1), R. Bisschops (2), V. Lepilliez (3), P. Leclercq (1) / [1] CHC, Liège, [2] UZ Leuven, [3] Hôpital Privé Jean Mermoz, Lyon, France
- 15:11 **Discussion**

15:21-16:12 - SESSION 2

Moderators : T. Moreels (UCL Saint-Luc, Brussels),
E. Toussaint (Hôpital Marie-Curie, Charleroi),
S. Ouazzani (ULB Erasme, Brussels)

- 15:21 **Invited Lecture: How to increase your diagnostic yield in EUS-FNA/B sampling? ESGE recommendations.**
Thomas Hucl / Prague, Czech Republic
- 15:36 G08 **EUS-guided gastroenterostomy versus duodenal stenting for malignant gastric outlet obstruction: an international, multicenter, propensity score-matched comparison.**
M. Bronswijk (1), R. Van Wanrooij (2), G. Vanella (3), P. De Gooyer (2), W. Laleman (1), H. Van Malenstein (1), F. Mandarino (3), G. Dell'anna (3), P. Fockens (2), P. Arcidiacono (3), S. Van Der Merwe (1), R. Voermans (2) / [1] UZ Leuven, [2] Amsterdam UMC, The Netherlands, [3] Vita Salute San Raffaele University, Milan, Italy
- 15:42 G09 **Safety and Efficacy of Double EUS-bypass versus Surgical Hepaticojejunostomy and Gastrojejunostomy.**
M. Bronswijk (1), J. Lauwereys (1), H. Van Malenstein (1), W. Laleman (1), J. Jaekers (1), H. Topal (1), B. Topal (1), R. Kunda (3), S. Van Der Merwe (1) / [1] UZ Leuven [2] [3] UZ Brussel
- 15:48 G10 **EUS Guided gastroenterostomy: Evolution of the technique to improve technical success (with video).**
L. Monino (1), T. Moreels (1), J. Gonzalez (2), H. Piessevaux (1), M. Barthet (2), P. Deprez (1) / [1] UCL Brussels, [2] Assistance Publique des hôpitaux de Marseille, Hôpital Nord, Marseille, France
- 15:54 G11 **EUS-guided transrectal drainage of pelvic abscesses: a retrospective analysis of 16 patients.**
H. Peeters (1), M. Simoens (2), J. Lenz (2) / [1] UZ Leuven, [2] ZNA Jan Palfijn, Merksem
- 15:58 G12 **Performance and applicability of a first generation single-use duodenoscope: a single-center cohort study.**
H. Van Malenstein (1), D. Persyn (2), A. Schuermans (1), M. Dreesen (1), W. Meert (1), K. Buysschaert (1), S. Van Der Merwe (1), W. Laleman (1) / [1] UZ Leuven, [2] AZ Damiaan, Oostende
- 16:02 **Discussion**

16:12-17:00 - SESSION 3

Moderators : P. Dewint (AZ Maria-Middelares, Gent),
C. Snauwaert (AZ Sint Jan Brugge-Oostende),
P. Leclercq (Hôpital Mont Legia, Liège)

- 16:12 **Invited Lecture: How to improve tissue sampling in Lower GI endoscopy? ESGE recommendations.**
Marietta Iacucci / Birmingham, UK
- 16:32 G13 **Dye another day: dye-based chromoendoscopy versus i-scan virtual chromoendoscopy in long-standing UC: A multicenter prospective randomized controlled trial.**
A. Jans (1), P. Sinouquel (1), M. Pierik (2), T. Seerden (3), S. Sloth (4), J. Karstensen (5), G. De Hertogh (6), I. Demedts (1), H. Willekens (6), S. Vermeire (1), R. Bisschops (1) / [1] UZ Leuven, [2] Maastricht University Medical Centre, The Netherlands, [3] Amphia Hospital Breda, The Netherlands, [4] Copenhagen University Hospital – Herlev and Gentofte, Hellerup, Denmark, [5] Copenhagen University Hospital - Amager and Hvidovre, København, Denmark, [6] UZ Leuven
- 16:38 G14 **Prediction of residual neoplasia after a non-curative colorectal ESD: a multicentric and multinational study.**
M. Figueiredo Ferreira (1), M. Pioche (2), F. Ramos-Zabala (3), P. Cecinato (4), F. Gallego (5), P. Barreiro (6), C. Félix (6), S. Sferrazza (7), F. Berr (8), A. Wagner (8), E. Albéniz (9), H. Uchima (10), R. Küttner-Magalhães (11), C. Fernandes (12), R. Morais (13), S. Gupta (14), M. Marques (13), M. Bourke (14), G. Macedo (13), A. Lemmers (1), J. Santos-Antunes (13) / [1] ULB Erasme, Bruxelles, [2] Edouard Herriot Hospital, Lyon, France, [3] University Hospital HM Montepíncipe, Madrid, Spain, [4] Azienda USL - IRCCS di Reggio Emilia, Italy, [5] Hospital de Poniente, Almería, Spain, [6] Centro Hospitalar Lisboa Ocidental, Portugal, [7] Santa Chiara Hospital, Trento, Italy, [8] University Clinics Salzburg, Austria, [9] Complejo Hospitalario de Navarra, Pamplona, Spain, [10] Hospital Universitario Germans Trias i Pujol, Barcelona, Spain, [11] Centro Hospitalar do Porto, Portugal, [12] Centro Hospitalar Vila Nova de Gaia/Espinho, Portugal, [13] University Hospital S o João , Porto, Portugal, [14] Westmead Hospital, Sydney, Australia
- 16:44 G15 **Development and validation of the Global Polypectomy Assessment Tool (GPAT) - a novel online assessment tool for any colorectal polypectomy.**
A. De Crem (1), D. Tate (2), L. Desomer (2) / [1] U Gent, [2] UZ Gent
- 16:50 G16 **A one-day virtual-live hybrid training course is feasible and has a positive impact on colonoscopy key performance indicators (KPI) amongst experienced endoscopic trainees.**
L. Krott (1), L. Debels (1), C. Schoonjans (1), R. Valori (2), J. Anderson (3), L. Desomer (4), D. Tate (1) / [1] UZ Gent, [2] Gloucestershire Hospitals NHS Foundation Trust, UK, [3] Cheltenham General Hospital, UK, [4] AZ Delta, Roeselare
- 16:54 G17 **Development and validation of a novel score for the completeness of caecal intubation score – the CCIS (completeness of caecal intubation score).**
L. Crapé (1), L. Debels (1), C. Schoonjans (2), L. Desomer (3), J. Anderson (4), R. Valori (4), D. Tate (1) / [1] UZ Gent, [2] AZ St. Jan Brugge, [3] AZ Delta, Roeselare, [4] Cheltenham General Hospital, UK
- 16:58 **Discussion**
- 17:08 **Award Ceremony
Best Abstract & Best Presentation**

E-POSTERS

- G23 **Analysis of factors influencing outcome of angiographic embolization for severe, gastroduodenal hemorrhage related to peptic ulceration.**
C. Vanhoenacker, E. Hufkens, I. Demedts, G. Maleux / UZ Leuven
- G24 **Digestive neo-epithelization after endoscopic stenting for complete upper digestive tract disunion.**
S. Ouazzani (1), A. Lemmers (1), J. Gonzalez (2), J. Closset (2), I. El Messaoui (2), J. Deviere (1), M. Barthet (2) / [1] ULB Erasme, Bruxelles, [2] Assistance Publique des hôpitaux de Marseille, Hôpital Nord, Marseille, France
- G25 **EUS-guided versus PTC-guided rendez-vous in case of failed ERCP: a case-control study.**
M. Hanssens, H. Degroote, P. Hindryckx / UZ Gent
- G26 **Lumen-apposing metal stents for the treatment of short refractory gastrointestinal strictures: a preliminary experience.**
P. Hindryckx, H. Degroote / UZ Gent
- G27 **Endoscopic exploration of the excluded stomach in patients with Roux-en-Y gastric bypass: comparison of single-balloon and motorized spiral enteroscopy.**
T. Moreels (1), L. Monino (1), P. Deprez (1), H. Piessevaux (1) / UCL Saint-Luc, Brussels
- G28 **First data of BOTOMY trial: descriptive interim results on clinical efficacy of intraplyoric Botulinum toxine injection and G-POEM in refractory gastroparesis.**
P. Corens (1), S. Bouhadan (1), H. De Schepper (1), P. Dewint (2) / [1] UZ Antwerpen, [2] Maria Middelaars Ziekenhuis, Gent
- G29 **Short double balloon enteroscopy assisted endoscopic retrograde cholangiopancreatography in patients with surgically altered anatomy.**
R. Wadhwa, A. Ravindranath / Apollo BGS Hospital, Mysore, India

08:45-12:10 - SESSION 1

Moderators : A. Driessen (UZ Antwerpen), P. Baldin (UCL Saint-Luc)

- 08:45 R01 **Stromal proliferations in gastric inverted polyps are Plexiform fibromyxoma-like rather than inflammatory myofibroblastic tumor-like.**
L. Libbrecht (1), T. Billiet (2) / [1] UCL Saint-Luc, Brussels, [2] AZ Groeninge, Kortrijk
- 09:00 R02 **Polypoid colon mucosa in a leukemia patient.**
I. Mariz (1), F. Lifrange (2), A. Van Gossum (1), L. Verset (1), D. Bron (1), M. Gomez-Galdon (1), P. Demetter (1) / [1] Institut Jules Bordet, Brussels, [2] CHU of Liège
- 09:15 R03 **Aseptic liver abscesses in newly diagnosed Crohn's disease.**
C. Vuckovic, A. Cremer / ULB Erasme, Bruxelles
- 09:30 **Invited Lecture: Ulcerative colitis or Crohn's disease, the interaction between endoscopist and pathologist.**
P. Bossuyt / Imelda general hospital, Bonheiden
- 10:00 **Invited Lecture: Ulcerative colitis or Crohn's disease, the pathologist contribution.**
R. Feakins / Royal Free Hospital, London, and University College London, UK
- 10:40 **BREAK**
- 10:55 **Invited Lecture: Which histologic features determine treatment and follow-up of the IBD-patient ?**
G. De Hertogh / UZ Leuven
- 11:25 R04 **During the course of the disease, IBD-patients may present with different complications.**
A. Vandendriessche, A. Jauregui-Amezaga, S. Van Den Broeck, A. Driessen / UZ Antwerpen
- 11:40 **Invited Lecture: IBD in children with special attention for very early onset IBD.**
P. Borralho-Nunes / Hospital Cuf Descobertas, Lisboa and Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal
- 12:10 **BREAK**

13:00-16:00 - SESSION 2

Moderators : L. Verset (Institut Jules Bordet), M. Carprieaux (ASZ Aalst)

- 13:00 R05 **Strongyloides stercoralis hyperinfection syndrome Mimicking severe acute colitis.**
M. Zeriouh, C. Liefferinckx, G. Englebert, M. Abdessalami, A. Cremer / ULB Erasme Bruxelles
- 13:15 R06 **Chronic ileitis, a challenging diagnosis for the pathologist.**
A. Francois, A. Wabik, H. Dano, O. Dewit, A. Kartheuser, A. Jouret-Mourin, P. Baldin / UCL Saint-Luc, Brussels
- 13:30 R07 **Sexually transmitted infectious colitis, a mimicker of Inflammatory bowel disease.**
J. Fallas (1), M. Bortes (2), P. Eisendrath (2), P. Demetter (1), L. Verset (1) / [1] Institut Jules Bordet, Brussels, [2] Hôpital Saint-Pierre
- 13:45 R08 **The great but rare mimicker.**
M. Vanhooren, M. Vanhooren / UZ Brussel
- 14:00 **Mimics of IBD.**
L. Verset / Institut Jules Bordet, Brussels
- 14:30 **BREAK**
- 14:45 R09 **Dysplasia in Crohn's disease: an infrequent diagnosis, not to miss.**
A. Sieben, A. Vandendriessche, E. Baetens, N. Komen, M. Somers, A. Driessen / UZ Antwerpen
- 15:00 **IBD-related dysplasia.**
A. Driessen / UZ Antwerpen
- 15:30 **IBD-related cancer.**
P. Demetter / Institut Jules Bordet, Brussels
- 16:00 **Closing remarks**

13:00-14:00 - SESSION 1: Vascular liver disease and portal hypertension

Moderators : C. Van Steenkiste (AZ Maria Middelaers/UZA), S. Lefere (UGent)

- 13:00 **A clinical update on vascular liver disease.**
Pierre-Emmanuel Rautou / Paris, France
- 13:30 **A translational update on portal hypertension and pathological vascular alterations.**
Sarah Raevens / UGent
- 14:00 **BREAK**

14:10-15:10 - SESSION 2: Clinical cases

Moderators : L. Van Melkebeke (UZ Leuven), D. Degre (ULB Erasme)

- 14:10 Y01 **Hemolytic anemia & cirrhosis : about a case.**
S. Ziane Bouziane (1), C. Lelubre (1), W. Soub Defeu (1), J. Cofino Casanueva(1), V. Chua (2) / [1] CHU de Charleroi, Hôpital Marie Curie, [2] UCL Saint-Luc, Brussels,
- 14:20 Y02 **Non-Alcoholic Steatohepatitis and bariatric surgery: an unwarranted improvement.**
I. Delaleeuwe, J. Aoun, T. Sersté, J. Mulkay, A. Hoyois, A. Cuvelier, P. Eisendrath / CHU Saint-Pierre, Brussels
- 14:30 Y03 **Recurrent Mycoplasma pneumoniae infection causing hepatitis and cholestasis in a young girl.**
E. Levy (1), Y. Vandenplas (2), K. Huysentruyt (2), E. De Greef (2) / [1] CHU Saint-Pierre, Brussels, [2] UZ Brussel
- 14:40 Y04 **Intrahepatic cholangiocarcinoma with predominant ductal plate malformation pattern: an unusual mimicker of benign lesion.**
F. Noel (1), O. Detry (1), C. Sampoux (2), N. Bletard (1) / [1] CHU of Liège, [2] CHUV Lausanne, Lausanne, Switzerland
- 14:50 Y05 **Autoimmune hepatitis developing after SARS-CoV-2 vaccination: series of three cases.**
G. Rasschaert (1), S. François (1), A. Verbeeck (2), M. Schils (1), M. Aert (1), P. Lefesvre (3), I. Colle (4), H. Reynaert (1) / [1] UZ Brussel, [2] ASZ Aalst, [3] UZ Brussel, [4] UZ Gent
- 15:00 Y06 **USP53 gene: The new kid on the block causing low GGT cholestasis.**
A. Ravindranath, R. Wadhwa, M. Wadhwa / Apollo BGS Hospital, Mysore, India
- 15:10 **BREAK**

15:15-16:30 - SESSION 3: Rising stars in the liver community

Moderators : V. De Smet (VUB), R. Bielen (UZ Leuven)

- 15:20 **Best Translational paper at BASL winter meeting:**
Intestinal permeability, microbial translocation, changes in duodenal and fecal microbiota, and their associations with alcoholic liver disease progression in humans.
Luca Maccioni / UCL
- 15:45 **Best Basic paper at BASL winter meeting:**
Diet Reversal and Immune Modulation Show Key Role for Liver and Adipose tissue T Cells in Murine NASH.
Mikhail Van Herck: onalcoholic Steatohepatitis / UAntwerpen
- 16:10 **Closing of meeting**

Moderators : R. Bisschops (UZ Leuven), E. Toussaint (CHU Charleroi),
M. Aerts (UZ Brussel), A. Lemmers (ULB Erasme)

Theme: Endoscopic tissue sampling: best practice and case discussion

How to sample or not a preneoplastic lesion

How to sample an advanced neoplastic lesion

EUS-FNA/FNB best practices

How to sample infectious and inflammatory diseases

- G18 **Exploration of the excluded stomach in a patient with Roux-en-Y gastric bypass: how to use the motorized spiral enteroscope.**
Moreels T., Monino L. / UCL Saint-Luc, Brussels
- G19 **Endoscopic submucosal dissection of a solitary gastric plasmocytoma: 'third space oddity'.**
Rasschaert G. (1), Gkolfakis P. (2), Eisendrath P. (3), Verset L. (1), Devière J. (2), Lemmers A. (2) / [1] CUB Institut Jules Bordet, Brussels, [2] CUB ULB Erasme, Brussels, [3] CHU Saint-Pierre, Brussels
- G20 **Salvage esophageal ESD for recurrence of superficial carcinoma on a ESD scar: an anatomical lesson of the microanatomy of esophageal re-epithelialisation.**
Charara F. (1), Eisendrath P. (1), Verset L. (2), Demetter P. (2), Lemmers A. (1) / [1] ULB Erasme, Brussels, [2] Institut Jules Bordet, Brussels
- G21 **The case of a scrutinized unusual duodenal tumor.**
Poiraud M. (1), Moulart F. (2), Verset L. (3), Lemmers A. (1), Eisendrath P. (2) / [1] ULB Erasme, Brussels, [2] ULB Saint-Pierre, Brussels, [3] Institut Jules Bordet, Brussels
- G22 **Endoscopic management of colorectal anastomotic leakage complicated with pelvic abscess: new strategy ? (with video)**
Monino L. (1), Moreels T. (1), Leonard D. (1), Kartheuser A. (1), Berdah S. (2), Barthet M. (2), Gonzalez J. (2) / [1] UCLouvain, Brussels, [2] Assistance Publique des hôpitaux de Marseille, Hôpital Nord, Marseille, France

13:30-15:30 : POSTGRADUATE SYMPOSIUM. FECAL INCONTINENCE.

**Moderators : S. Van den Broeck (Digestive Surgery, UZ Antwerpen),
C. Van Kemseke (Gastroenterology, CHU Liege)**

- **13:30** **Remember the basics: pathophysiology and workup of fecal incontinence.**
M.-A. Denis / UCL Saint Luc
- **14:00** **Fecal incontinence in neurological disease.**
B. Willekens / UZ Antwerpen
- **14:30** **BREAK**
- **14:45** **Conservative treatment of fecal incontinence.**
P. Roelandt / UZ Leuven
- **15:15** **Sacral neuromodulation: mechanisms, indications and results.**
D. Vandeputt / UZ Gent

- 08:00 - 08:30 **Satellite Symposium EISAI/MSD:**
Time to Reflect: The convenient choice of systemic treatment in uHCC.
 Speaker: Ivan Borbath (UCL Saint-Luc)



09:00-09:50 - SESSION 1

**Moderators : V. Casneuf (OLV, Aalst),
 J.-L. Van Laethem (ULB Erasme, Brussels)**

- 08:30 **Introduction**
- 08:35 O01 **Therapeutic yield of comprehensive molecular profiling in cholangiocarcinoma: a retrospective single center study.**
 J. Vancanneyt, B. Wilmsen, C. Luyten, C. Verslype, E. Van Cutsem, T. Roskams, S. Tejpar, I. Vanden Bempt, J. Dekerverl / UZLeuven
- 08:45 **Invited Lecture: Future directions in targeted therapies in Cholangiocarcinoma.**
 Angela Lamarca / The Christie NHS Foundation Trust, Manchester, UK
- 09:15 O02 **Determination of the histological growth patterns of colorectal peritoneal metastases and evaluation of their prognostic impact.**
 A. El Asmar (1), P. Demetter (1), F. Fares (2), F. Sciafani (1), A. Hendlisz (1), D. Larsimont (1), V. Donckier (1), G. Liberale (1) / [1] Institut Jules Bordet, [2] ULB Erasme
- 09:25 O03 **Homogeneity of pathological response and histopathological growth pattern in resected colorectal liver metastases is associated with favorable survival outcome after surgery.**
 P. Baldin (1), G. Beniuga (2), J. Carrasco (3), A. De Cuyper (1), I. Sinapi (3), C. Hubert (1), B. Navez (1), M. Castella (1), A. Van Maanen (1), B. Mlecnik (4), A. Jouret-Mourin (2), M. Van Den Eynde (1) / [1] UCL Saint-Luc, Brussels, [2] IPG, Charleroi, [3] GHDC, Charleroi, [4] Université Paris Descartes, Paris, France
- 09:35 **Invited Lecture: Role of the clinical pathologist in decision-making in metastatic colorectal cancer.**
 Pamela Baldin / UCL Saint Luc, Brussels

■ 10:05 BREAK

- 10:05 - 10:35 **Satellite Symposium BMS:**
Upper GI and CPS : A Ping Pong game between a Pathologist and an Oncologist.
 Speakers: R. Salgado (ZNA-GZA) and
 J. Dekerverl (UZ Leuven)



10:50-13:00 - SESSION 2

Moderators : L. Mortier (AZ St Maarten, Mechelen),
M. VandenEynde (UCL Sain- Luc, Brussels)

- 10:50 O04 **Clinical impact of 99mTc-MAA SPECT/CT-based personalized predictive dosimetry in selective internal radiotherapy: a retrospective, single-center study for unresectable HCC patients.**
A. Bucalau (1), B. Collette (2), I. Tancredi (2), M. Vouche (3), M. Pezzullo (2), R. Moreno-Reyes (2), N. Trotta (2), J. Van Laethem (2), G. Verset (2) / [1] ULB Erasme, Brussels, [2] CUB Erasme, [3] CUB Institut Jules Bordet, Brussels
- 11:00 **Invited Lecture: The emergence of personalized radioembolisation therapy.**
Christophe Derooze / UZLeuven
- 11:30 O05 **Development of a novel off-the-shelf cell-based immunotherapy to eradicate CD70-positive cancer associated fibroblasts in metastatic colorectal cancer.**
A. Van Den Eynde, J. Van Audenaerde, J. De Waele, H. Lau, J. Jacobs, M. Peeters, F. Lardon, E. Smits, P. Pauwels / U Antwerpen / UZ Antwerpen
- 11:40 O06 **Introduction of percutaneous Stereotactic MicroWave Ablation (SMWA) as alternative for liver resection in malignant liver tumors during pandemic hospital restrictions.**
T. Chapelle, B. Op De Beeck, B. Bracke, M. Niekel, V. Van Reeth, R. Dankerlui, G. Roeyen, V. Hartman, A. Snoeckx, D. Ysebaert / UZ Antwerpen
- 11:50 **Outstanding Lectures on COVID 19 pandemics and Cancer Care: What Cancer Registry evolution under COVID-19 pandemics tells us about future cancer care in Belgium.**
Liesbet van Eycken / Cancer Registry
- 12:30 **BGDO trophy, communications, and Chairman conclusions**
- 13:00 **End of the session**

E-POSTERS

- O07 **Deep epigastric lymph node (DELN) basin as a possible systemic metastatic pathway of peritoneal metastases: a retrospective analysis on patients with recurrent peritoneal carcinomatosis.**
A. El Asmar, M. Vouche, M. Gomez Galdon, M. Bali, D. Larsimont, F. Sclafani, A. Hendlisz, V. Donckier, G. Liberale / Institut Jules Bordet, Brussels
- O08 **Following therapy response through liquid biopsies in metastatic colorectal cancer patients: the lead-in FOLICOLOR trial.**
K. Janssens, K. Op De Beeck, S. Raats, S. Wouters, G. Van Camp, M. Peeters / UAntwerp/ UZ Antwerpen
- O09 **Using CT scans to measure sarcopenia in digestive cancer patients.**
A. Van Oosterwyck, K. Plovie, M. Cool, G. Deboever, G. Lambrecht / AZ Damiaan, Oostende
- O10 **Occurrence and treatment of brain metastases in patients with digestive cancers – a single centre retrospective review.**
I. Ould-Nana, D. Castanares Zapatero, I. Borbath, A. De Cuyper, M. Vandeneynde / UCL Saint-Luc, Brussels
- O11 **A systematic review to predict the outcome of phase III clinical trials in GI Oncology.**
G. Bregni, R. Saúde Conde, G. Rasschaert, T. Akin Telli, A. Hendlisz, F. Sclafani / Institut Jules Bordet, Brussels
- O12 **Initial establishment of patient-derived organoids as a novel model for neuroendocrine neoplasms.**
O. Islam, V. Timon, M. Lecompte, C. Deben, G. Roeyen, N. Komen, S. Peeters, F. Rodrigues Fortes, M. Peeters, W. Lybaert, H. Prenen, F. Lardon, A. Driessen, M. Huizing / UZ Antwerpen
- O13 **Identification and quantification of the microbiome in colorectal cancer metastases.**
P. Stevens (1), V. Llorens-Rico (2), P. Baldin (3), L. Craciun (4), S. Gofflot (5), F. George (6), J. Sadones (7), M. Buys (8), F. Sandras (9), J. Raes (2), M. Van Den Eynde (1) / [1] UCL Saint Luc, Brussels, [2] KU Leuven, [3] UCL Saint Luc, Brussels, [4] Institut Jules Bordet, Brussels, [5] CHU Liège, [6] CHU UCL Namur, [7] UZ Brussel, [8] UZ Antwerpen, [9] ULB Erasme, Brussels
- O14 **Therapeutic yield of comprehensive molecular profiling in cholangiocarcinoma: a retrospective single center study.**
J. Vancanneyt, B. Wilmsen, C. Luyten, C. Verslype, E. Van Cutsem, T. Roskams, S. Tejpar, I. Vanden Bempt, J. Dekervel / UZ Leuven

SESSION 1

Moderators : P. Deprez (UCL Saint-Luc, Brussels), F. Berrevoet (UZ Gent)

- 14:00 **Invited Lecture:**
PERT in Pancreatic Cancer.
Dr Vera Hartman (UZA, Antwerpen)
- 14:20 P01 **Long-term outcomes after EUS-guided pancreatic duct drainage.**
M. Van Haren, T. Aouattah, T. Moreels, R. Yeung, P.H. Deprez / UCL Saint-Luc, Brussels
- 14:32 P02 **Intravenous Hemin, a potential Heme oxygenase-1 activator, does not protect from post-ERCP acute pancreatitis in human: results of a randomized multicentric multinational placebo controlled trial.**
R. Yared (1), C. Chen (2), A. Vandorpe (1), M. Arvanitakis (1), M. Delhayé (1), M. Fernandez Y Viesca (1), V. Huberty (1), D. Blero (1), E. Toussaint (3), A. Hittelet (5), D. Verset (6), W. Margos (6), O. Le Moine (1), H. Njimi (7), W. Liao (2), J. Devière (1), A. Lemmers (1) / [1] ULB Erasme, Brussels, [2] National Taiwan University Hospital, Taipei,decine , [3] Hôpital Marie Curie, Charleroi, [4] CHU Ambroise Paré, Mons, [6] Jolimont-Lobbes, La Louvière
- 14:44 P03 **Irreversible electroporation in the multidisciplinary approach of peripancreatic tumors. An initial experience.**
J. Dubart (1), C. Bertrand (1), L. D'hondt (1), C. Schalbar (2), L. Faugeras (1), M. Mailleux (3), A. Dili (1) / [1] CHU-UCL, Yvoir, [2] Centre Hospitalier du Nord, Ettelbruck, Luxembourg, [3] UCL Saint-Luc, Namur
- Best paper 2021 session**
- 15:00 **Clinical pancreatology** P.H. Deprez (UCL Saint-Luc, Brussels)
- 15:10 **Pancreatic endoscopy** M. Fernandez Y Viesca (ULB Erasme, Brussels)
- Battle session**
- 15:20 **Management of surgical fistulas: Prevention, timing and treatment Surgeon**
Surgeon
F. Berrevoet (UZGent)
Endoscopist
H van Malenstein (KULeuven)
- State of the Art invited lecture**
- 15:50 **Why and how to build a pancreas expert center?**
E. Domínguez-Muñoz / Santiago de Compostela, Spain
- Case sessions**
- 15:50 **Dilated MPD with intraductal material: two possible scenarios.**
M. Fernandez, M. Delhayé, P. Loi, J. Closset, J. Navez, M. Pezzullo, N. D'haene, M. Arvanitakis / ULB Erasme, Brussels
- 16:28 **Chronic pancreatitis and pancreatic cancer: a challenging diagnosis.**
M. Fernandez (1), M. Delhayé (1), M. Pezzullo (1), P. Demetter (2), M. Arvanitakis (1) / (1) ULB Erasme, Brussels, (2) Institut Jules Bordet, Brussels.
- 16:36 **Tissue is the issue?**
G. Bastens, N. Bletard, P. Leclercq, C Coibion, F Jehaes, R. Materne, O. Plomteux, G. Matus, B. Bastens /CHC, Liège
- 16:44 P04 **Duodenal duplication cyst causing recurrent acute pancreatitis : Case report and endoscopic treatment (with video).**
S. Lorea (1), R. Garces Duran (1,2), T. De Grez (3), D. Blero (1) / [1] ULB Erasme, Brussels, [2] UCL Saint-Luc, Brussels, [3] CHR Namur
- 16:52 P05 **Looking for the needle in a haystack.**
M. VANHOOREN /UZ Brussel
- 17:00 **End of the meeting**

WITH THE KIND SUPPORT OF

PLATINUM



GOLD

abbvie

 Bristol Myers Squibb™

 HEALTHCARE
CELLTRION

 MSD 

PENTAX
MEDICAL

SANDOZ



 VIATRIS™

SILVER

ACTA GASTRO-ENTEROLOGICA •
GILEAD • IPSEN • OLYMPUS • NORGINE •
PFIZER • SERVIER

BRONZE

BIOCODEX • BAYER • COOK MEDICAL • DR FALK PHARMA •
ECHOSENS • ERBE • GBS-VBS • MADRIGAL •
MAYOLY BENELUX • PILEJE • RVC SOFTWARE

XXXIVth Edition – 09 > 11.02.22 – A DIGITAL EXPERIENCE

BWGE Event Coordination : DME Events • Anne-France De Meyer • 57 av. G Demey 1160 Bruxelles •
anne.france.de.meyer@dme-events.eu • Tel : 0477 27 00 45